Supernus Pharmaceuticals Current Ratio 2011-2024 | SUPN

Supernus Pharmaceuticals current ratio from 2011 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Supernus Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2024-06-30 $0.59B $0.31B 1.92
2024-03-31 $0.54B $0.32B 1.73
2023-12-31 $0.49B $0.29B 1.70
2023-09-30 $0.45B $0.29B 1.56
2023-06-30 $0.42B $0.25B 1.68
2023-03-31 $0.88B $0.73B 1.21
2022-12-31 $0.73B $0.69B 1.07
2022-09-30 $0.66B $0.73B 0.91
2022-06-30 $0.63B $0.74B 0.85
2022-03-31 $0.57B $0.29B 2.00
2021-12-31 $0.60B $0.32B 1.91
2021-09-30 $0.67B $0.24B 2.85
2021-06-30 $0.64B $0.28B 2.26
2021-03-31 $0.59B $0.24B 2.43
2020-12-31 $0.63B $0.25B 2.57
2020-09-30 $0.55B $0.30B 1.84
2020-06-30 $0.56B $0.27B 2.07
2020-03-31 $0.56B $0.17B 3.31
2019-12-31 $0.47B $0.16B 2.94
2019-09-30 $0.43B $0.15B 2.85
2019-06-30 $0.39B $0.14B 2.72
2019-03-31 $0.42B $0.15B 2.77
2018-12-31 $0.49B $0.16B 3.06
2018-09-30 $0.39B $0.14B 2.82
2018-06-30 $0.29B $0.10B 2.74
2018-03-31 $0.58B $0.12B 4.90
2017-12-31 $0.23B $0.12B 1.86
2017-09-30 $0.19B $0.11B 1.82
2017-06-30 $0.17B $0.09B 1.94
2017-03-31 $0.15B $0.08B 1.83
2016-12-31 $0.15B $0.08B 1.88
2016-09-30 $0.14B $0.07B 1.93
2016-06-30 $0.11B $0.07B 1.69
2016-03-31 $0.09B $0.06B 1.69
2015-12-31 $0.11B $0.06B 1.86
2015-09-30 $0.10B $0.04B 2.35
2015-06-30 $0.11B $0.04B 2.89
2015-03-31 $0.10B $0.03B 3.69
2014-12-31 $0.11B $0.03B 3.87
2014-09-30 $0.10B $0.02B 4.65
2014-06-30 $0.07B $0.02B 3.75
2014-03-31 $0.08B $0.03B 2.95
2013-12-31 $0.10B $0.03B 3.68
2013-09-30 $0.10B $0.03B 4.10
2013-06-30 $0.11B $0.02B 6.90
2013-03-31 $0.08B $0.03B 2.83
2012-12-31 $0.09B $0.02B 3.98
2012-09-30 $0.06B $0.03B 2.56
2012-06-30 $0.08B $0.02B 3.56
2012-03-31 $0.04B $0.02B 1.93
2011-12-31 $0.05B $0.02B 2.63
2011-09-30 $0.00B 0.00
2011-06-30 $0.00B 0.00
2011-03-31 $0.00B 0.00
2010-12-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.872B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00